Rates of ERBB2 Alterations Across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-amplified Acral Melanoma.

CONCLUSIONS: ERBB2 amplification is present in a minority of acral lentiginous and mucosal melanomas. Activating mutations in ERBB2 were identified in non-uveal melanoma subtypes and are frequently co-mutated with canonical drivers. HER2 could represent a therapeutically relevant target across melanoma subtypes.
PMID: 30093446 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 9, 2018 Category: Cancer & Oncology Authors: Gottesdiener LS, O'Connor S, Busam KJ, Won H, Solit DB, Hyman DM, Shoushtari AN Tags: Clin Cancer Res Source Type: research